October 25, 2014 12:29 PM ET


Company Overview of Altheos, Inc.

Company Overview

Altheos, Inc., an early-stage biopharmaceutical company, engages in the identification and development of small molecule drugs for the treatment of glaucoma and ocular hypertension. It develops ATS907 and ATS8535, a selective Rho kinase inhibitor for treatment of elevated intraocular pressure associated with glaucoma. The company was founded in 2009 and is based in South San Francisco, California.

601 Gateway Boulevard

Suite 250

South San Francisco, CA 94080

United States

Founded in 2009





Key Executives for Altheos, Inc.

Chief Executive Officer and Director
Age: 55
President and Chief Scientific Officer
Chief Medical Officer
Director of Corporate Administration
Executive Director of Product Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Trophogen, Inc. United States
Cardigant Medical Inc. United States
Upstate Group, Inc. United States
AbVitro, Inc. United States
Cognate BioServices, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Altheos, Inc., please visit www.altheos.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.